Galena Biopharma (SLS)
(Delayed Data from NSDQ)
$1.21 USD
-0.25 (-17.12%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $1.22 +0.01 (0.83%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SLS 1.21 -0.25(-17.12%)
Will SLS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLS
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
Galena Biopharma, Inc. (SLS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
SLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SLS
12 Health Care Stocks Moving In Monday's Intraday Session
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
Sellas Life Sciences announces positive review of ongoing Phase 3 REGAL trial
SELLAS Life Sciences announces IDMC's recommendation of continuing REGAL phase 3 study without modifications
Solaris Resources Reports Encouraging Drilling Results